<DOC>
	<DOC>NCT01276639</DOC>
	<brief_summary>The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.</brief_summary>
	<brief_title>A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Are 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering as least 10%of body surface area a Psoriasis Area and Severity Index (PASI) score of 12 and are considered to be candidates for systemic or light therapy No evidence of active or latent tuberculosis Nonplaque or drug induced forms of psoriasis cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB) any uncontrolled significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Xeljanz</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>chronic</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Itch</keyword>
	<keyword>DLQI</keyword>
	<keyword>severe</keyword>
	<keyword>moderate</keyword>
	<keyword>treatment</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>CP-690,550</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Jax-inhibitor</keyword>
	<keyword>Oral Treatment</keyword>
</DOC>